Home Stock

Stock Research: Glenmark Pharmaceuticals

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Glenmark Pharmaceuticals

NSI:GLENMARK INE935A01035
55
  • Value
    22
  • Growth
    92
  • Safety
    Safety
    20
  • Combined
    37
  • Sentiment
    44
  • 360° View
    360° View
    55
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. It operates in branded, generics, and OTC segments, focusing on Respiratory, Dermatology, Oncology, diabetes, cardiovascular, and oral contraceptives, with brands like RYALTRIS and SALMEX/ASTHMEX. The company develops products for markets such as India, Russia & CIS, Brazil, Asia, and Africa. In the last fiscal year, the company had a market cap of $7238 million, profits of $1050 million, and revenue of $1559 million.

more

ANALYSIS: With an Obermatt 360° View of 55 (better than 55% compared with alternatives), overall professional sentiment and financial characteristics for the stock Glenmark Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Glenmark Pharmaceuticals. The consolidated Growth Rank has a good rank of 92, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 92% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 22 means that the share price of Glenmark Pharmaceuticals is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 78% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 20, which means that the company has a riskier financing structure than 80% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 44, indicating professional investors are more pessimistic about the stock than for 56% of alternative investment opportunities. ...read more

more
Strongest Rank Market Pulse
Weakest Rank Growth
Country India
Industry Pharmaceuticals
Size Large
Website glenmarkpharma.com
Index
Glenmark Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 9-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
22 59 71 87
Growth
92 77 23 37
Safety
Safety
20 18 44 29
Sentiment
44 61 32 14
360° View
360° View
55 66 28 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
61 60 31 42
Opinions Change
50 50 38 35
Pro Holdings
n/a 25 21 26
Market Pulse
16 96 73 47
Sentiment
44 61 32 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
22 59 71 87
Growth
92 77 23 37
Safety Safety
20 18 44 29
Combined
37 54 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
33 62 84 91
Price vs. Earnings (P/E)
40 64 75 89
Price vs. Book (P/B)
20 59 81 87
Dividend Yield
29 18 23 40
Value
22 59 71 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
78 67 28 16
Profit Growth
61 98 26 53
Capital Growth
58 3 6 72
Stock Returns
91 95 95 33
Growth
92 77 23 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
70 46 26 18
Refinancing
33 28 76 84
Liquidity
48 14 38 24
Safety Safety
20 18 44 29

Similar Stocks

Discover high‑ranked alternatives to Glenmark Pharmaceuticals and broaden your portfolio horizons.

SBI Life Insurance

NSI:SBILIFE
Country: India
Industry: Life & Health Insurance
Size: Large
Full Stock Analysis

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Mega Lifesciences

SET:MEGA
Country: Thailand
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

CESC

NSI:CESC
Country: India
Industry: Electric Utilities
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only positive is high growth. The stock is expensive (low Value Rank), risky to finance, and carries critical professional sentiment. This is a risky proposition. Avoid unless you have exceptional conviction that the growth alone will overcome the price and financial risks.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews